Synergy of Combined tPA-Edaravone Therapy in Experimental Thrombotic Stroke

Edaravone, a potent antioxidant, may improve thrombolytic therapy because it benefits ischemic stroke patients on its own and mitigates adverse effects of tissue plasminogen activator (tPA) in preclinical models. However, whether the combined tPA-edaravone therapy is more effective in reducing infar...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Yu-Yo, Morozov, Yury M., Yang, Dianer, Li, Yikun, Dunn, R. Scott, Rakic, Pasko, Chan, Pak H., Abe, Koji, Lindquist, Diana M., Kuan, Chia-Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4049665/
https://www.ncbi.nlm.nih.gov/pubmed/24911517
http://dx.doi.org/10.1371/journal.pone.0098807

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4049665/
https://www.ncbi.nlm.nih.gov/pubmed/24911517
http://dx.doi.org/10.1371/journal.pone.0098807

Ejemplares similares